focus -WSS

focus

author：fashion 2025-09-28 21:11:46 - browse：9843

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The strategy behind pharma's lawsuits over drug pricing reform

WSS

With FDA staff opposed to Sarepta therapy, top official intervened

Restaurant meals are packed with calories, and we still keep eating them

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Many breast cancer patients receive more radiation than needed

STAT's guide to the next generation of CAR

How CRISPR works, explained in two minutes

explore

focus

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

WATCH: Why do fingernails fall off when they're damaged?

Psychedelics group wrestles with new pharma identity

Flash flood warnings continue for parts of Missouri, Illinois

The cancer drug shortage isn’t new — and neither are the solutions

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

How one medical school became remarkably diverse

Trump used to be more articulate. What could explain the change?

DIEP, the 'gold standard' of breast reconstruction, is under threat

The science behind Janet Jackson's pregnancy at 49

hotspot

In areas with more Black doctors, Black people live longer

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Why are elite athletes different? Take a look at their microbes

Failure, not just success, should guide future doctors

Many breast cancer patients receive more radiation than needed

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Wikipedia

focus

knowledge

Wikipedia